Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC.
NCT ID: NCT04640935
Last Updated: 2020-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
320 participants
OBSERVATIONAL
2019-10-01
2020-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.
For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.
The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.
As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
* Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
* Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
* Alive patients not opposed to the use of their data
Exclusion Criteria
* Patients alive at the time of the study who are opposed to the use of their data
* Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Centre Hospitalier Annecy Genevois
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chantal Decroisette
Role: PRINCIPAL_INVESTIGATOR
CH Annecy Genevois
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Ambroise Paré AP-HP
Boulogne-Billancourt, , France
Centre Hospitalier Universitaire Brest
Brest, , France
Centre Hospitalier Métropole Savoie
Chambéry, , France
Centre Hospitalier Intercommunal de Créteil
Créteil, , France
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, , France
Centre Hospitalier de Versailles André Mignot
Le Chesnay, , France
Centre Hospitalier Universitaire de Lille
Lille, , France
Centre Léon Bérard Lyon
Lyon, , France
Hospices Civils de Lyon
Lyon, , France
Centre Hospitalier François Quesnay
Mantes-la-Jolie, , France
Centre Hospitalier Annecy Genevois
Metz-Tessy, , France
Institut Curie
Paris, , France
Institut Curie Saint Cloud
Saint-Cloud, , France
Institut de Cancérologie Lucien Neuwirth
Saint-Etienne, , France
Hôpital Foch
Suresnes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-09
Identifier Type: -
Identifier Source: org_study_id